KUALA LUMPUR: The Health Ministry has agreed to grant conditional registration approval for the product Evusheld 100 milligrammes per millimetre (mg/ml) Solution For Injection (Tixagevimab 100 mg/ml and Cilgavimab 100 mg/ml) manufactured by Astrazeneca AB of Sweden.
Health director-general Tan Sri Dr Noor Hisham Abdullah said the product was used to prevent Covid-19 infection following pre-exposure prophylaxis of Covid-19 to adults and adolescents aged 12 and above weighing at least 40kg.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
